Mylan/Agila Merger Requires Fourth Largest Divestiture In Generic Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC mandates that the two companies sell off 11 generic injectable drugs as a condition for allowing their merger; Intas, Sagent, JHP Pharmaceuticals and Gland Pharma are to acquire the products.